Stocktoria
ACTUATE THERAPEUTICS, INC. ACTU
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2024-08-13
ACTUATE THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D expense | $10.3M | $18.7M | $21.7M |
| Operating income | -$22.5M | -$25.2M | -$25.0M |
| Income tax | $800 | $800 | $0 |
| Net income | -$22.2M | -$27.3M | -$24.7M |
| EPS (diluted) | $-1.06 | $-3.26 | $-17.24 |
| Operating cash flow | -$19.2M | -$21.8M | -$21.6M |
| Cash & equivalents | $13.2M | $8.6M | — |
| Total assets | $14.0M | $9.3M | $3.0M |
| Total liabilities | $6.1M | $9.2M | $8.4M |
| Shareholders' equity | $7.9M | $104,186 | -$99.6M |
Source: SEC EDGAR filings · CIK 0001652935 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.